Shots:

• BMS signed a definitive merger agreement to acquire Karuna to strengthen its neuroscience portfolio by gaining the rights over Karuna’s lead neuroscience assets incl. KarXT, an antipsychotic
• As per the terms of the agreement, BMS will acquire all the outstanding shares of Karuna common stock for $330/share in cash for a total equity value of ~$14B or $12.7B net of estimated cash acquired. The transaction is expected to close by H1’24
• The US FDA has accepted Karuna's NDA filing for KarXT to treat schizophrenia (PDUFA date Sep 26, 2024). Moreover, KarXT is also being assessed in a registrational trial for adjunctive therapy to existing SoC agents in schizophrenia & to treat psychosis in patients with Alzheimer’s disease

Ref: BMS | Image: BMS

Related News:- Karuna Therapeutics Reports the NDA Submission of KarXT to the US FDA for the Treatment of Schizophrenia

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com